(AOF) – Sensorion has net available cash of 37 million euros, and says it is capable of meeting its cash flow needs beyond the next twelve months, i.e. until the end of the second quarter of 2025, in particular thanks to to the proceeds of the private placement of 50.5 million euros, announced on February 9, 2024. The biotech specializing in hearing disorders posts a net loss of 22.1 million euros in 2023, compared to 23.2 million in 2022. In 2024, Sensorion plans to “continue the development of its entire portfolio”.
“Sensorion is equipped to meet its operational objectives for 2024, continue to provide innovative therapeutic solutions to patients in the field of hearing and create value for its shareholders,” said Nawal Ouzren, Managing Director of Sensorion. “Over the past few months, Sensorion has successfully completed all of the major milestones set out on its roadmap.”
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
